Catalyst overview
Research summary
This catalyst tracks a PDUFA approval decision for SKYRIZI/Risankizumab (N/A) (IL-23 Inhibitor) in Crohn's Disease. The expected timing is based on the latest available company guidance and may change.
03/02/26:- AFFIRM Ph3 (NCT06063967) topline positive; SC induction superior vs placebo at Week 12. Full results later. 04/27/26:- FDA filing for SC induction; AbbVie anticipates approval later in 2026. 05/05/26:- DDW posters show ASPIRE-CD year 1 symptom and QoL gains; US claims show low switching.
Verification
Confirm timing and program details against the company announcement or filing.